EGFR-IN-57

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

EGFR-IN-57 

EGFR-IN-57 (Compound 25a) 是一种有效的、具有口服活性的 EGFR-TK 抑制剂，IC50 值为 0.054 µM。EGFR-IN-57 也抑制 VEGFR-2、CK2α、topoisomerase IIβ 和 tubulin polymerization，IC50 值分别为 0.087、0.171、0.13 和 3.61 µM。EGFR-IN-57 诱导细胞 G2/M 和 pre-G1 期周期阻滞，诱导癌细胞凋亡 (apoptosis)。

EGFR-IN-57

EGFR-IN-57 Chemical Structure

CAS No. : 2492382-37-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis[1].

IC50 & Target

EGFR

0.054 μM (IC50)

VEGFR-2

0.087 μM (IC50)

CK2α

0.171 μM (IC50)

topoisomerase II beta

0.13 μM (IC50)

tubulin polymerization

3.16 μM (IC50)

分子量

385.44

Formula

C22H15N3O2S
CAS 号

2492382-37-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Warda ET, et al. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. Bioorg Med Chem. 2020 Nov 1;28(21):115674.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复